US2022241291A1PendingUtilityA1

Oxygen linked pyrimidine derivatives

67
Assignee: CTI BIOPHARMA CORPPriority: Nov 16, 2005Filed: Sep 2, 2021Published: Aug 4, 2022
Est. expiryNov 16, 2025(expired)· nominal 20-yr term from priority
C07D 515/16C07D 498/16C07D 515/18A61K 31/5377C07D 498/06C07D 498/18A61K 31/519C07D 498/08
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumours and cancers as well as other disorders or conditions related to or associated with kinases.

Claims

exact text as granted — not AI-modified
1 .- 138 . (canceled) 
     
     
         139 . A compound having a structure according to the following formula:

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.